CVR number 34044341
Industry 72.1100 Research and experimental development on biotechnology

BKG VET PHARMA ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Bankruptcy risk for industry  1.2% 1.2% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 36.4% 28.3% 41.1%  
Credit score (0-100)  0 0 1 3 0  
Credit rating  N/A N/A C B C  
Credit limit (kDKK)  0.0 0.0 -0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -94.2 -151 -36.0  
EBITDA  0.0 0.0 -94.2 -151 -36.0  
EBIT  0.0 0.0 -8,445 -407 -36.0  
Pre-tax profit (PTP)  0.0 0.0 -8,430.3 -385.7 -38.4  
Net earnings  0.0 0.0 -6,128.0 -329.3 -94.8  
Pre-tax profit without non-rec. items  0.0 0.0 -8,430 -386 -38.4  
 
See the entire income statement

Balance sheet (kDKK) 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 850 521 226  
Interest-bearing liabilities  0.0 0.0 242 0.0 0.0  
Balance sheet total (assets)  0.0 0.0 1,452 602 249  
Net Debt  0.0 0.0 87.0 -516 -249  
 
See the entire balance sheet

Volume 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -94.2 -151 -36.0  
Gross profit growth  0.0% 0.0% 0.0% -60.2% 76.1%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 1,452 602 249  
Balance sheet change%  0.0% 0.0% 0.0% -58.5% -58.7%  
Added value  0.0 0.0 -94.2 7,943.8 -36.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 -8,351 -256 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 8,965.8% 269.9% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -580.7% -35.5% -8.5%  
ROI %  0.0% 0.0% -772.2% -45.3% -9.7%  
ROE %  0.0% 0.0% -721.0% -48.1% -25.4%  

Solidity 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Equity ratio %  0.0% 0.0% 58.5% 86.4% 90.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -92.4% 342.0% 690.9%  
Gearing %  0.0% 0.0% 28.4% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.8% 17.2% 0.0%  

Liquidity 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Quick Ratio  0.0 0.0 2.4 7.4 10.7  
Current Ratio  0.0 0.0 2.4 7.4 10.7  
Cash and cash equivalent  0.0 0.0 154.8 516.0 249.1  

Capital use efficiency 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 849.9 520.6 225.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0